List of Excipients in Branded Drug INDIUM IN 111 CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Curium US LLC	INDIUM IN 111 CHLORIDE	indium in 111 chloride	69945-132	HYDROCHLORIC ACID

Indium In-111 Chloride Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Indium In-111 chloride is a radiopharmaceutical precursor rather than a conventional finished therapeutic. Its commercial value comes from enabling the preparation of indium-111-labeled diagnostic agents, including peptide, antibody, and cell-labeling products. The excipient strategy is therefore narrow: maintain radionuclide stability, minimize competing metals, preserve chelator compatibility, and avoid formulation components that interfere with radiolabeling or patient administration.

What is Indium In-111 Chloride used for?

Indium In-111 chloride is a sterile radioactive solution of indium-111 in hydrochloric acid and water. It is used to radiolabel approved pharmaceutical kits or other validated ligand systems before administration to patients.

Indium-111 has a physical half-life of approximately 67.3 hours and emits principal gamma photons at approximately 171 keV and 245 keV. Those emissions support single-photon emission computed tomography and planar imaging.[1]

Core applications

Application	Representative labeled product or approach	Commercial status
Somatostatin receptor imaging	Indium-111 pentetreotide, historically marketed as OctreoScan	Established diagnostic application
Antibody imaging	Indium-111 capromab pendetide, marketed as ProstaScint	Historical or limited commercial relevance
Leukocyte labeling	Indium-111 oxine or related cell-labeling systems	Hospital and nuclear-medicine use
Experimental peptide imaging	In-111-DTPA, DOTA, and related chelator conjugates	Clinical development and specialty use
Research and central laboratory imaging	Radiolabeled antibodies, peptides, and cells	Research, contract manufacturing, and clinical-trial demand

The chloride solution is not generally positioned as a standalone imaging agent. It is an input into a radiolabeling process.

What excipients are present in Indium In-111 Chloride Injection?

The basic formulation uses hydrochloric acid and water for injection. The acidic medium stabilizes indium ions and helps prevent hydrolysis or precipitation before the radionuclide is transferred into a validated labeling system.[2]

Typical formulation architecture

Component	Function	Commercial and regulatory rationale
Indium-111 chloride	Radioactive active ingredient and labeling source	Supplies the radionuclide
Hydrochloric acid	Maintains acidic pH and indium solubility	Supports chemical stability during storage
Water for injection	Vehicle	Enables sterile parenteral handling
Chelator in the receiving kit	Binds indium-111	Usually supplied in the separate radiolabeling kit
Buffer in the receiving kit	Adjusts final labeling and administration pH	Must be compatible with chelation and injection
Stabilizer or excipient in the receiving kit	May control aggregation or oxidation	Product-specific and not inherent to the chloride precursor

The formulation generally avoids preservatives, surfactants, excess phosphate, and competing metal ions. Those materials can reduce labeling efficiency, alter biodistribution, or interfere with chelation.

Why the precursor has a sparse excipient profile

Indium-111 chloride is handled as a radiolabeling reagent. Adding conventional formulation excipients would create several risks:

1. The excipient may compete with DTPA, DOTA, or another chelator for indium.
2. The excipient may alter the final pH after labeling.
3. The excipient may increase the impurity profile of the radiolabeled product.
4. The excipient may complicate sterility, endotoxin, and radionuclidic-purity testing.
5. The excipient may create an additional component for radiation-degradation studies.

The best commercial formulation is usually the simplest formulation that preserves radionuclide stability through shipment and supports high radiochemical yield at the point of use.

How should an excipient strategy be designed for In-111 radiolabeling?

The preferred strategy is to separate precursor stability from final-patient formulation. The chloride precursor should remain acidic and metal-controlled, while the receiving kit contains the chelator, ligand, buffer, and any product-specific stabilizers.

1. Control trace metals

Trace metals are a central quality risk. Iron, zinc, copper, calcium, and other cations can occupy chelators or reduce radiolabeling efficiency. Manufacturing should use low-metal-contact materials, qualified water systems, controlled raw materials, and validated cleaning procedures.

For a commercial supplier, low-metal specifications can create a defensible quality advantage even when the base formulation is chemically simple.

2. Preserve chelator compatibility

The precursor should be compatible with the major indium-binding systems used in nuclear medicine:

• DTPA and DTPA derivatives
• DOTA and DOTA derivatives
• Desferrioxamine derivatives
• Other validated macrocyclic or acyclic chelators

DOTA generally requires more demanding labeling conditions than DTPA, including elevated temperature or longer reaction time in some systems. A precursor supplier that offers defined activity concentration, low-metal content, and consistent acidity can improve the reproducibility of downstream kits.

3. Minimize radiolysis and adsorption

Indium-111 solutions can experience radiolysis during storage, especially at higher activity concentrations. Commercial development should evaluate:

• Container surface adsorption
• Silicone-oil interaction in syringes
• Vial closure compatibility
• Activity concentration at calibration and expiry
• Radiolytic impurity formation
• Recovery after storage and transport
• pH drift over the labeled shelf life

A low-binding container system can be commercially relevant where the product is shipped in small-volume, high-activity presentations.

4. Avoid unnecessary buffering in the precursor

A buffered precursor may appear more patient-friendly, but it can reduce flexibility for downstream radiolabeling. The final labeled drug must be adjusted to a suitable pH using the receiving kit or a validated post-labeling process.

For most applications, the buffer belongs in the kit rather than in the indium chloride vial.

What FDA regulatory status applies to Indium In-111 Chloride?

Indium In-111 Chloride Injection is regulated as a prescription radiopharmaceutical component used in the preparation of radiolabeled drugs. Its labeling and manufacturing controls are governed by FDA requirements for drug products, sterile products, radiopharmaceuticals, and current good manufacturing practice.[2,3]

Regulatory characteristics

Issue	Implication
Dosage form	Sterile injectable radioactive solution
Primary use	Radiolabeling precursor
Administration	Usually indirect, through a labeled pharmaceutical product
Manufacturing controls	Sterility, endotoxins, radionuclidic identity, radionuclidic purity, chemical purity, activity concentration
Distribution	Requires radioactive-material licensing and specialized logistics
Stability	Driven by physical decay, chemical stability, radiolysis, and container compatibility
Labeling	Must define handling, calibration, storage, expiry, and radiolabeling instructions

A developer launching a new In-111 chloride product would need to address both ordinary injectable-drug requirements and radioactive-material controls. The product must also align with the compatibility requirements of the downstream labeled drug.

What is the Orange Book status of Indium In-111 Chloride?

The Orange Book is not the principal commercial-exclusivity tool for In-111 chloride. The precursor is a mature radiopharmaceutical component, and market access is driven more by manufacturing authorization, radioactive-material licensing, quality consistency, distribution capability, and downstream kit demand than by an active compound patent.

The commercially relevant IP is more likely to cover:

• Radiolabeling kits
• Chelator-ligand conjugates
• Antibody or peptide constructs
• Cell-labeling methods
• Formulations of the final labeled product
• Automated radiochemistry systems
• Manufacturing and purification methods

A standalone patent on indium-111 chloride as a radioactive isotope solution would generally provide limited protection because the chemical concept is established and the product is difficult to differentiate by composition alone.

What patents protect In-111 labeled products?

Patent value is concentrated downstream from the chloride precursor.

Formulation patents

Potentially valuable claims may cover:

• Specific chelator-to-ligand ratios
• Stabilized radiolabeled peptide formulations
• Low-volume injectable compositions
• pH and buffer systems
• Antioxidants or radical scavengers
• Adsorption-reducing container systems
• Lyophilized kits for later reconstitution with In-111 chloride

A formulation patent is strongest when it links a defined composition to improved radiochemical yield, reduced aggregation, enhanced stability, or improved imaging performance.

Method-of-use patents

Method claims may cover:

• Imaging somatostatin receptor-positive tumors
• Imaging prostate-specific membrane antigen or other tumor targets
• Imaging infection or inflammation
• Labeling and tracking autologous leukocytes
• Patient-selection methods based on receptor expression
• Dosimetry-guided diagnostic or therapeutic workflows

Many historical method-of-use positions have limited remaining commercial value because the underlying imaging applications are mature. Newer value may arise from companion-diagnostic uses, theranostic selection, and targeted imaging in specific cancer populations.

Manufacturing and process patents

Process protection may cover:

• Production of high-purity In-111 chloride
• Target irradiation and radionuclide recovery
• Separation of cadmium and indium
• Removal of competing metals
• Automated kit reconstitution
• Sterile filtration and aseptic radiolabeling
• Waste reduction and activity recovery

Process patents can matter commercially even when composition claims are weak, particularly where the process improves yield, radionuclidic purity, or delivery reliability.

How strong is the patent estate for Indium In-111 Chloride?

The direct patent estate for the precursor is likely weak relative to the patent estates surrounding newer radioligands and biologics. The strongest barriers are operational and regulatory.

Relative protection by layer

Protection layer	Relative strength	Reason
In-111 isotope itself	Low	Established radionuclide and public scientific knowledge
Acidic chloride precursor	Low	Simple, mature composition
High-purity manufacturing process	Moderate	Process know-how and validated controls can be difficult to replicate
Chelator-ligand kit	Moderate to high	Product-specific composition and process claims
Radiolabeled antibody or peptide	Moderate to high	May include composition, use, and manufacturing claims
Automated radiochemistry platform	Moderate	Hardware, software, and process integration can create switching costs
Supply chain and distribution	High operational value	Short half-life limits practical substitution

Commercial defensibility depends less on blocking patents and more on reliable production, hospital relationships, regulatory history, and supply continuity.

When does Indium In-111 Chloride lose exclusivity?

There is no single biologic-style or small-molecule-style exclusivity date that controls the entire In-111 chloride market. The relevant exclusivity periods differ by product layer.

Layer	Exclusivity driver
Indium-111 chloride precursor	Regulatory approval, manufacturing authorization, and supply capability
Radiolabeled kit	Product patents, regulatory exclusivity, and approved labeling
Peptide or antibody ligand	Composition-of-matter and use patents
Hospital preparation method	Institutional procedures and applicable process IP
New imaging indication	Method-of-use patents and regulatory exclusivity

The physical half-life also limits practical market reach. Inventory cannot be held for long periods, and products must be manufactured and shipped close to the time of use.

Which companies are positioned in the In-111 commercial market?

The market includes radiopharmaceutical manufacturers, nuclear pharmacy operators, kit developers, academic radiochemistry groups, and specialized contract manufacturers.

Commercial participants

• Curium and other established radiopharmaceutical suppliers may compete in radionuclide production and distribution.
• Large nuclear-medicine companies may supply labeled products or radionuclide precursors.
• Hospital radiopharmacies may perform final labeling under approved procedures.
• Specialty biotechnology companies may develop In-111-labeled peptides, antibodies, or cell-labeling agents.
• Contract development and manufacturing organizations may provide GMP radiolabeling and sterile fill-finish services.

Competition is regional because radioactive shipments are time-sensitive. A supplier with a technically equivalent product may still be commercially disadvantaged if it lacks local production or dependable same-day delivery.

What commercial opportunities exist in excipients and formulation systems?

The largest opportunity is not a new excipient for the chloride solution. It is the development of enabling systems around the precursor.

Opportunity areas

Ready-to-label kits

Kits containing a validated chelator-ligand system, buffer, stabilizer, and instructions can increase adoption. The value proposition is operational simplicity, consistent radiochemical yield, and reduced pharmacist labor.

Metal-controlled excipient packages

Suppliers can offer qualified buffers, water systems, vials, and closures with low levels of competing metals. These products can be sold as part of a radiopharmaceutical manufacturing platform.

Stabilizers for labeled products

The receiving product may require a stabilizer to control radiolysis, aggregation, or oxidation. Candidate categories include carefully selected antioxidants, amino acids, polyols, and protein-stabilizing excipients. Each must be tested for chelation interference, radiation degradation, and injection safety.

Low-adsorption containers

Container systems designed for low protein or peptide adsorption can reduce activity loss. Vials, syringes, and tubing are potential product opportunities, especially for low-volume or high-value labeled products.

Automated labeling consumables

Closed-system cassettes, disposable reaction vessels, sterile connectors, and dose-calibration interfaces can create recurring revenue. These products may be more defensible than commodity excipients because they integrate with validated workflows.

Radiolabeling quality-control services

Commercial laboratories can provide radiochemical purity, radionuclidic purity, endotoxin, sterility, and stability testing. Small radiopharmaceutical developers often need outsourced testing because conventional analytical infrastructure is not optimized for short-lived radionuclides.

What generic entry risks exist for In-111 chloride?

Generic entry risk is technically moderate but commercially constrained.

A competitor can potentially replicate the basic formulation, but must demonstrate:

• Comparable radionuclidic purity
• Reliable activity calibration
• Sterility and endotoxin control
• Container closure integrity
• Acceptable chemical purity
• Stable shipping performance
• Licensed radioactive-material operations
• Consistent delivery to nuclear pharmacies and hospitals

The principal risk to an incumbent is usually supply substitution rather than a patent-driven generic launch. A new supplier may enter with a lower price, broader geographic coverage, or improved activity availability.

What licensing deals are relevant?

Licensing value typically sits with the downstream ligand or kit, not with the indium chloride precursor. A precursor manufacturer can create commercial leverage through:

• Exclusive supply agreements with kit developers
• Co-development of In-111-labeled imaging agents
• Regional distribution rights
• Contract manufacturing for clinical-trial batches
• Joint development of automated radiolabeling systems
• Bundled supply of precursor, kit, and quality-control materials

A long-term supply agreement can be more important than a patent license because dependable radionuclide access is essential for clinical operations.

What does the competitive landscape look like versus other radionuclides?

Attribute	In-111	Technetium-99m	Gallium-68	Fluorine-18
Half-life	67.3 hours	6.0 hours	67.7 minutes	109.8 minutes
Common imaging mode	SPECT	SPECT	PET	PET
Supply model	Central production and shipment	Generator and reactor supply	Generator or cyclotron	Cyclotron
Labeling chemistry	Strong for DTPA/DOTA systems	Broad kit ecosystem	Increasing DOTA use	Covalent synthesis
Logistics	More forgiving than short-lived PET isotopes	Frequent delivery required	Highly time-sensitive	Highly time-sensitive
Commercial growth	Specialty and legacy imaging	Large established market	Expanding theranostic market	Large PET market

In-111 has a logistical advantage over gallium-68 and fluorine-18 because its half-life allows broader shipment windows. It has a competitive disadvantage in imaging sensitivity and market momentum compared with PET radionuclides.

Key Takeaways

• Indium In-111 chloride is primarily a radiolabeling precursor, not a conventional finished diagnostic drug.
• The base formulation is intentionally simple, generally relying on hydrochloric acid and water for injection.
• Excipient innovation is more valuable in the receiving kit, final labeled formulation, container system, and automated radiochemistry workflow.
• Trace-metal control is a critical technical and commercial differentiator.
• Direct composition patents on In-111 chloride are likely to provide limited protection.
• The stronger IP positions are associated with chelator-ligand constructs, imaging methods, kit formulations, and manufacturing processes.
• FDA approval, radioactive-material licensing, quality systems, and regional distribution create the main entry barriers.
• Commercial opportunities include ready-to-label kits, metal-controlled materials, low-adsorption containers, radiolysis stabilizers, automation consumables, and GMP quality-control services.
• Competitive pressure from gallium-68 and other PET radionuclides limits long-term growth in some imaging indications.
• Reliable supply and geographic coverage can have greater commercial value than precursor patent exclusivity.

FAQs

Can Indium In-111 Chloride be administered directly to patients?

It is generally supplied as a precursor for radiolabeling an approved pharmaceutical, rather than as the final imaging agent. The labeled product determines the clinical indication and administration procedure.

Which chelators are most relevant to In-111 radiopharmaceuticals?

DTPA and DOTA derivatives are among the most relevant chelation systems. The appropriate chelator depends on the ligand, labeling conditions, stability requirements, and intended clinical use.

Is a preservative useful in In-111 chloride formulations?

A preservative is generally unattractive because the product is a sterile radiolabeling precursor, often used in small volumes and under controlled nuclear-pharmacy conditions. Preservatives can complicate compatibility and regulatory characterization.

Can In-111 chloride support theranostic development?

It can support diagnostic imaging and patient-selection strategies for ligand-targeted programs. Therapeutic development generally uses a different radionuclide, such as lutetium-177 or actinium-225, paired with a related ligand.

What is the most defensible commercial position for an In-111 supplier?

The strongest position combines validated radionuclide quality, low-metal manufacturing, dependable regional distribution, ready-to-label kit partnerships, and integration with hospital or nuclear-pharmacy workflows.

References

1. International Atomic Energy Agency. (2020). Indium-111. IAEA Live Chart of Nuclides. https://www-nds.iaea.org/relnsd/vcharthtml/VChartHTML.html

2. U.S. Food and Drug Administration. (n.d.). Indium In-111 Chloride Injection prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2023). Current good manufacturing practice for drugs. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

4. U.S. Pharmacopeia. (2024). General chapter <825>: Radiopharmaceuticals: Preparation, compounding, dispensing, and repackaging. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (n.d.). OctreoScan prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/